Cost-Effectiveness of Adjunctive Therapy with Atypical Antipsychotics for Acute Treatment of Major Depressive Disorder

Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants

(2016) Robert M. Berman et al.   CNS SPECTRUMS

In This Issue

(2010)   AMERICAN JOURNAL OF PSYCHIATRY

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study

(2010) Nizar El-Khalili et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Extended-Release Quetiapine as Adjunct to an Antidepressant in Patients With Major Depressive Disorder

(2009) Michael Bauer et al.   JOURNAL OF CLINICAL PSYCHIATRY

The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder

(2009) Ronald N. Marcus et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study

(2009) Marianne Ulcickas Yood et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY